



Research Day

WMU Homer Stryker M.D. School of Medicine

2017

Mixed Goblet Cell Carcinoid-Adenocarcinoma: A Case Series

Jairo Espinosa M.D.

Western Michigan University Homer Stryker M.D. School of Medicine

Timothy Truong

Western Michigan Homer Stryker M.D. School of Medicine

Julia Miladore M.D.

Western Michigan Homer Stryker M.D. School of Medicine

John T. Collins

Borgess Medical Center

Saad Shebrain M.D.

Western Michigan Homer Stryker M.D. School of Medicine

See next page for additional authors

Follow this and additional works at: https://scholarworks.wmich.edu/medicine_research_day



Part of the Life Sciences Commons, and the Surgery Commons

WMU ScholarWorks Citation

Espinosa, Jairo M.D.; Truong, Timothy; Miladore, Julia M.D.; Collins, John T.; Shebrain, Saad M.D.; and Munene, Gitonga M.D., "Mixed Goblet Cell Carcinoid-Adenocarcinoma: A Case Series" (2017). *Research Day*. 24.

https://scholarworks.wmich.edu/medicine_research_day/24

This Abstract is brought to you for free and open access by the WMU Homer Stryker M.D. School of Medicine at ScholarWorks at WMU. It has been accepted for inclusion in Research Day by an authorized administrator of ScholarWorks at WMU. For more information, please contact wmu-scholarworks@wmich.edu.



Authors

Jairo Espinosa M.D., Timothy Truong, Julia Miladore M.D., John T. Collins, Saad Shebrain M.D., and Gitonga Munene M.D.

Mixed Goblet Cell Carcinoid-Adenocarcinoma – A Case Series

Jairo A. Espinosa MD, Timothy Truong, Julia Miladore MD, Saad Shebrain MD
 Gitonga Munene MD, John T. Collins MD

INTRODUCTION

Mixed goblet cell carcinoid-adenocarcinoma (GCC) tumors are a group of rare heterogeneous neoplasms of the appendix first described in 1969 by Gagne et al that account for < 5% of all primary appendiceal tumors.^{1,2} These hybrid tumors are characterized as an intermediate between classic carcinoid tumors and appendiceal adenocarcinomas, exhibiting both neuroendocrine and glandular/mucinous morphology that most commonly presents in Caucasian females in the fifth and sixth decades.^{1,3-6} Their distinct glandular and neuroendocrine differentiation has led to multiple names and designations including adenocarcinoids, mucinous-carcinoid, mixed carcinoid-adenocarcinoma, microglandular goblet cell carcinoma, and crypt cell adenocarcinoma.⁷ A broader classification system has been suggested for GCC tumors based on their histologic appearance.³ The system classifies the tumors into 3 sub-groups: typical goblet cell carcinoid (Group A), adenocarcinoma ex-goblet cell carcinoid; signet-ring cell type (group B), and adenocarcinoma ex-goblet cell carcinoid; poorly differentiated carcinoma type (group C).³ The most common presentation for GCC tumors is acute appendicitis.^{3,8} We present three cases of mixed goblet cell carcinoid-adenocarcinoma presenting as acute appendicitis.

CASE PRESENTATIONS

Case #1 involved a 65-year-old male who presented with right lower quadrant pain, nausea, emesis, and leukocytosis. A CT scan of the abdomen revealed perforated appendicitis. The patient underwent a laparoscopic appendectomy. Pathology revealed a high-grade adenocarcinoma ex goblet cell carcinoid, signet ring type extending through the muscularis propria and into the mesoappendix measuring >3cm. The patient subsequently underwent a colonoscopy that revealed diverticulosis involving the sigmoid colon, but was otherwise normal. Labs revealed that CEA, CA-125, and chromogranin A were negative. Patient then underwent an exploratory laparotomy with a right hemicolectomy and partial omentectomy. Pathology revealed normal ileal and colonic mucosa without evidence of carcinoma. Omental specimen showed no evidence of metastatic carcinoma. 0/12 nodes were positive for metastatic carcinoma.




Image 1. CT imaging displaying acute appendicitis




Image 2. H & E stain demonstrating clusters of goblet cells invading the muscular wall of the appendix as seen in Group A mixed goblet cell carcinoid-adenocarcinoma¹²

Case #2 involved a 49-year-old male who presented with periumbilical pain, nausea, emesis, and leukocytosis. A CT scan of the abdomen revealed appendicitis. The patient underwent an uneventful laparoscopic appendectomy. Pathology revealed a high-grade, poorly differentiated, adenocarcinoma ex goblet cell carcinoid invading through the muscularis propria and into the periappendiceal soft tissue measuring 1.5cm. The patient subsequently underwent a colonoscopy that revealed diverticulosis involving the sigmoid colon, but was otherwise normal. Patient then underwent an uneventful laparoscopic right hemicolectomy. Pathology revealed normal ileal and colonic mucosa without evidence of carcinoma. 0/14 nodes were positive for metastatic carcinoma.

Case #3 involved a 70-year-old female who presented with periumbilical pain. A CT scan of the abdomen revealed appendicitis. The patient underwent an uneventful laparoscopic appendectomy. Pathology revealed a high-grade adenocarcinoma ex goblet cell carcinoid extending through the muscularis propria and into the mesoappendix measuring 4cm. Patient then underwent an exploratory laparotomy with a right hemicolectomy. Pathology revealed normal ileal and colonic mucosa without evidence of carcinoma. 0/21 nodes were positive for metastatic carcinoma.

Stage	T	N	M
I	T1: Tumor <2cm	N0	M0
II	T2 or T3 T2: Tumor 2-4cm T3: Tumor >4cm	N0	M0
III	ANY T T4: Tumor invading adjacent organs	N1: Metastasis to regional LN's	M0
IV	Any T	Any N	M1

Table 1. TNM Staging of Mixed Goblet Cell Carcinoid-Adenocarcinoma

CONCLUSION

Mixed goblet cell carcinoid-adenocarcinoma tumors are rare tumors that tend to present at an advanced stage with up to 40% positive lymphadenopathy and most commonly spread via direct extension.⁸ Surgical resection with a right hemicolectomy after an appendectomy has been shown to improve the prognosis and is thus recommended in most cases.^{9,10} HIPEC and adjuvant chemotherapy are other therapeutic options, but have not been shown to improve survival.¹¹ The adjuvant chemotherapy recommended composes of 5-fluorouracil (5-FU), FOLFOX (5-FU, leucovorin, and oxaliplatin), and FOLFIRI (5-FU, folic acid, and irinotecan).^{7,9} In the current age of increasing rates of managing acute appendicitis non-operatively we strongly encourage surgical appendectomy in patients older than 45 years of age to avoid missing this important diagnosis and the opportunity to treat it in a timely manner.

REFERENCES

- McGory ML, Maggard MA, Kang H, O'Connell JB, Ko CY. Malignancies of the Appendix: Beyond Case Series Reports. *Dis Colon Rectum*. 2005;48(12):2264-2271. doi:10.1007/s10350-005-0196-4.
- Gagné F, Fortin P, Dufour V, Delage C. [Tumors of the appendix associating histologic features of carcinoid and adenocarcinoma]. *Ann Anat Pathol (Paris)*. 14(4):393-406. http://www.ncbi.nlm.nih.gov/pubmed/5378353. Accessed February 11, 2017.
- Tang LH, Shia J, Soslow RA, et al. Pathologic Classification and Clinical Behavior of the Spectrum of Goblet Cell Carcinoid Tumors of the Appendix. *Am J Surg Pathol*. 2008;32(10):1429-1443. doi:10.1097/PAS.0b013e31817f1816.
- Reid MD, Basturk O, Shaib WL, et al. Adenocarcinoma ex-goblet cell carcinoid (appendiceal-type crypt cell adenocarcinoma) is a morphologically distinct entity with highly aggressive behavior and frequent association with peritoneal/intra-abdominal dissemination: an analysis of 77 cases. *Mod Pathol*. 2016;29(10):1243-1253. doi:10.1038/modpathol.2016.105.
- McCusker ME, Coté TR, Clegg LX, Sobin LH. Primary malignant neoplasms of the appendix. *Cancer*. 2002;94(12):3307-3312. doi:10.1002/cncr.10589.
- Pahlavan PS, Kanthan R. Goblet cell carcinoid of the appendix. *World J Surg Oncol*. 2005;3(1):36. doi:10.1186/1477-7819-3-36.
- Taggart MW, Abraham SC, Overman MJ, Mansfield PF, Rashid A. Goblet Cell Carcinoid Tumor, Mixed Goblet Cell Carcinoid-Adenocarcinoma, and Adenocarcinoma of the Appendix: Comparison of Clinicopathologic Features and Prognosis. *Arch Pathol Lab Med*. 2015;139(6):782-790. doi:10.5858/arpa.2013-0047-OA.
- Shenoy S. Goblet cell carcinoids of the appendix: Tumor biology, mutations and management strategies. *World J Gastrointest Surg*. 2016;8(10):660-669. doi:10.4240/wjgs.v8.i10.660.
- Pape U-F, Perren A, Niederle B, et al. ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejunum-ileum and the appendix including goblet cell carcinomas. *Neuroendocrinology*. 2012;95(2):135-156. doi:10.1159/000335629.
- Boudreaux JP, Klimstra DS, Hassan MM, et al. The NANETS Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors. *Pancreas*. 2010;39(6):753-766. doi:10.1097/MPA.0b013e3181eb2a25.
- Lamarca A, Nonaka D, Lopez Escola C, et al. Appendiceal Goblet Cell Carcinoids: Management Considerations from a Reference Peritoneal Tumour Service Centre and ENETS Centre of Excellence. *Neuroendocrinology*. 2016;103(5):500-517. doi:10.1159/000440725.
- Goblet Cell Carcinoid, Group A." *Webpathology.com: A Collection of Surgical Pathology Images*. N.p., n.d. Web. 14 Mar. 2017.